HLS Therapeutics Inc (HLS) Price & Analysis

Compare

44 Followers

HLS Stock Chart & Stats

C$5.00

C$0.04(1.06%)

At close: Jan 08 4:00 PM EST

C$5.00

C$0.04(1.06%)

Day’s Range― - ―

52-Week RangeC$3.20 - C$5.77

Previous CloseN/A

Volume4.75K

Average Volume (3M)19.90K

Market Cap

C$169.51M

Enterprise ValueC$211.13M

Total Cash (Recent Filing)C$12.15M

Total Debt (Recent Filing)C$55.57M

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Mar 12, 2026

EPS Estimate

-0.04

Last Dividend Ex-Date

Apr 27, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding31,275,282

10 Day Avg. Volume21,807

30 Day Avg. Volume19,898

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)1.22

Price to Sales (P/S)1.54

P/FCF Ratio10.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$7.06

Price Target Upside41.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceHLS announced a new, larger credit facility with superior terms, improving its cash flow and supporting future share repurchase and portfolio expansion efforts.

Regulatory ApprovalsHealth Canada has approved NILEMDO (bempedoic acid) for the reduction of LDL-Cholesterol in individuals at risk of cardiovascular disease.

Strategic Business DevelopmentHLS's capital allocation program has been effective, as it continues to buy back stock, pay down debt, and expand its portfolio through strategic in-licensing deals.

Bears Say

Generic CompetitionSome smaller members of the group have added generic clozapine to their formularies.

Regulatory ChallengesThe combo drug NEXLIZET (bempedoic acid and ezetimibe) received a notice of non-compliance (NON) from the regulator.

Revenue Performance3Q total revenues were $13.5M, down 4.1% Y/Y on an as reported basis.

HLS Therapeutics Inc News

Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals

David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on HLS Therapeutics Inc. The associated...

4d ago

HLS Therapeutics Gains Health Canada Approval for NILEMDO®

An update from HLS Therapeutics Inc ( ($TSE:HLS) ) is now available. HLS Therapeutics Inc. announced that Health...

6d ago

HLS Therapeutics Inc.: Strategic Resilience and Growth Potential Amidst Market Challenges

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on HLS Therapeutics Inc, with a price...

6d ago

HLS Therapeutics Reports Mixed Earnings Amid Growth Challenges

Hls Therapeutics (($TSE:HLS)) has held its Q3 earnings call. Read on for the main highlights of the call....

11d ago

HLS Therapeutics Reports Strong Q3 2025 Results and Prepares for New Product Launch

An announcement from HLS Therapeutics Inc ( ($TSE:HLS) ) is now available. HLS Therapeutics Inc. reported a strong...

11d ago

HLS Upcoming Earnings Report: What to Expect?

Hls Therapeutics (HLS) is scheduled to report 3rd quarter earnings on 11/13/2025, before the market opens. Regarding Q3...

13d ago

HLS Therapeutics to Announce Q3 2025 Financial Results

HLS Therapeutics Inc ( ($TSE:HLS) ) has issued an announcement. HLS Therapeutics Inc. announced it will release its...

25d ago

HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress

An announcement from HLS Therapeutics Inc ( ($TSE:HLS) ) is now available. HLS Therapeutics Inc., in collaboration with...

1M ago

HLS Therapeutics Secures New Credit Agreement for Financial Flexibility

HLS Therapeutics Inc ( ($TSE:HLS) ) has provided an announcement. HLS Therapeutics Inc. has announced a new credit...

3M ago

HLS Therapeutics Inc: Strong Q2 Performance and Optimistic Outlook Justify Buy Rating

Bloom Burton analyst David Martin PhD maintained a Buy rating on HLS Therapeutics Inc on August 15 and...

3M ago

HLS FAQ

What was HLS Therapeutics Inc’s price range in the past 12 months?

HLS Therapeutics Inc lowest stock price was C$3.20 and its highest was C$5.76 in the past 12 months.

What is HLS Therapeutics Inc’s market cap?

HLS Therapeutics Inc’s market cap is C$169.51M.

When is HLS Therapeutics Inc’s upcoming earnings report date?

HLS Therapeutics Inc’s upcoming earnings report date is Mar 12, 2026 which is in 108 days.

How were HLS Therapeutics Inc’s earnings last quarter?

HLS Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -C$0.168 earnings per share for the quarter, missing the consensus estimate of -C$0.087 by -C$0.081.

Is HLS Therapeutics Inc overvalued?

According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does HLS Therapeutics Inc pay dividends?

HLS Therapeutics Inc pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here

What is HLS Therapeutics Inc’s EPS estimate?

HLS Therapeutics Inc’s EPS estimate is -0.04.

How many shares outstanding does HLS Therapeutics Inc have?

HLS Therapeutics Inc has 31,275,282 shares outstanding.

What happened to HLS Therapeutics Inc’s price movement after its last earnings report?

HLS Therapeutics Inc reported an EPS of -C$0.168 in its last earnings report, missing expectations of -C$0.087. Following the earnings report the stock price went down -7.588%.

Which hedge fund is a major shareholder of HLS Therapeutics Inc?

Currently, no hedge funds are holding shares in TSE:HLS

HLS Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-20.49%

Trailing 12-Months

Asset Growth

-22.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HLS Therapeutics Inc

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

HLS Therapeutics Inc (HLS) Earnings & Revenues

Historic Earnings Reports

HLS Stock 12 Month Forecast

Average Price Target

C$7.06

▲(41.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"C$2","13":"C$13","4.75":"C$4.75","7.5":"C$7.5","10.25":"C$10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$7.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.75,7.5,10.25,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.58,6.073846153846154,6.567692307692308,7.061538461538461,7.555384615384615,8.04923076923077,8.543076923076923,9.036923076923078,9.53076923076923,10.024615384615384,10.518461538461539,11.012307692307692,11.506153846153847,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.58,5.693846153846154,5.8076923076923075,5.921538461538462,6.035384615384615,6.149230769230769,6.263076923076923,6.3769230769230765,6.490769230769231,6.604615384615384,6.718461538461538,6.832307692307692,6.9461538461538455,{"y":7.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.58,5.458461538461538,5.336923076923077,5.2153846153846155,5.093846153846154,4.972307692307693,4.850769230769231,4.729230769230769,4.607692307692307,4.486153846153846,4.364615384615385,4.243076923076924,4.121538461538462,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.15,"date":1706745600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >